VC gi­ant NEA backs an up­start’s plan to tack­le neu­rode­gen­er­a­tion

Neu­rode­gen­er­a­tive dis­eases are both one of the tough­est chal­lenges in drug de­vel­op­ment as well as po­ten­tial­ly one of the most lu­cra­tive fields in the busi­ness. If you can fig­ure out what the bad play­ers are that trig­ger dam­age, and come up with a drug to halt or even mod­est­ly slow that process, you could have a block­buster on your hands.

But then there’s a long line of com­pa­nies that have tried and failed at it, blow­ing bil­lions in the process.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.